Krystal Biotech Reaches Analyst Target Price
May 23, 2023 at 07:25 AM EDT
In recent trading, shares of Krystal Biotech Inc (KRYS) have crossed above the average analyst 12-month target price of $112.14, changing hands for $117.53/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..